Shares of Blueprint Medicines Corp (NASDAQ:BPMC) traded up 5% on Wednesday . The company traded as high as $84.44 and last traded at $84.01. 524,256 shares traded hands during trading, an increase of 14% from the average session volume of 461,778 shares. The stock had previously closed at $80.01.

A number of analysts have recently weighed in on the stock. DA Davidson assumed coverage on shares of Blueprint Medicines in a report on Friday, September 29th. They set a “buy” rating and a $90.00 target price for the company. BTIG Research assumed coverage on shares of Blueprint Medicines in a report on Friday, September 29th. They set a “buy” rating and a $90.00 target price for the company. Cowen reiterated a “buy” rating on shares of Blueprint Medicines in a report on Tuesday, October 31st. Zacks Investment Research lowered shares of Blueprint Medicines from a “hold” rating to a “sell” rating in a report on Thursday, November 2nd. Finally, Goldman Sachs Group reiterated a “buy” rating and set a $79.00 target price (up from $64.00) on shares of Blueprint Medicines in a report on Wednesday, September 20th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and ten have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $83.78.

The company has a debt-to-equity ratio of 0.02, a current ratio of 11.28 and a quick ratio of 11.28. The company has a market capitalization of $3,600.00 and a price-to-earnings ratio of -24.56.

Blueprint Medicines (NASDAQ:BPMC) last issued its quarterly earnings data on Tuesday, October 31st. The biotechnology company reported ($0.96) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.90) by ($0.06). Blueprint Medicines had a negative return on equity of 43.11% and a negative net margin of 437.83%. The company had revenue of $8.07 million during the quarter, compared to analysts’ expectations of $5.35 million. During the same quarter last year, the business earned ($0.62) earnings per share. The business’s quarterly revenue was up 31.0% on a year-over-year basis. equities research analysts predict that Blueprint Medicines Corp will post -3.75 earnings per share for the current fiscal year.

In other Blueprint Medicines news, insider Anthony L. Boral sold 5,000 shares of the firm’s stock in a transaction dated Monday, November 6th. The shares were sold at an average price of $70.40, for a total value of $352,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Marion Dorsch sold 18,334 shares of the firm’s stock in a transaction dated Tuesday, November 21st. The stock was sold at an average price of $65.45, for a total transaction of $1,199,960.30. Following the completion of the sale, the insider now owns 18,334 shares of the company’s stock, valued at $1,199,960.30. The disclosure for this sale can be found here. Insiders sold 63,783 shares of company stock valued at $4,340,192 over the last 90 days. 3.40% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently modified their holdings of BPMC. Rockefeller Financial Services Inc. bought a new position in shares of Blueprint Medicines during the third quarter valued at approximately $160,000. Turner Investments LLC bought a new position in shares of Blueprint Medicines during the third quarter valued at approximately $209,000. Great West Life Assurance Co. Can increased its stake in shares of Blueprint Medicines by 53.6% during the third quarter. Great West Life Assurance Co. Can now owns 3,332 shares of the biotechnology company’s stock valued at $228,000 after purchasing an additional 1,163 shares in the last quarter. Ameritas Investment Partners Inc. increased its stake in shares of Blueprint Medicines by 68.9% during the second quarter. Ameritas Investment Partners Inc. now owns 3,410 shares of the biotechnology company’s stock valued at $173,000 after purchasing an additional 1,391 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. bought a new position in shares of Blueprint Medicines during the third quarter valued at approximately $244,000. Institutional investors and hedge funds own 83.54% of the company’s stock.

WARNING: “Blueprint Medicines (BPMC) Trading 5% Higher” was reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/blueprint-medicines-bpmc-trading-5-higher/1793494.html.

About Blueprint Medicines

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with Analyst Ratings Network's FREE daily email newsletter.